First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
Open accessThe DOI matches its Crossref record.
Abstract
APX001 is a first-in-class, intravenous (IV) and oral (PO) broad-spectrum antifungal agent in clinical development for the treatment of invasive fungal infections (IFIs) due to Candida, Aspergillus and rare molds. The active moiety APX001A inhibits Gwt1, an early step in glycosylphosphatidylinositol (GPI) anchor biosynthesis. Excellent in vivo efficacy has been demonstrated in murine models of IFIs with APX001A AUC0–24 target exposures ranging from 2 to 80 µg hours/mL. There were six single ascending dose (SAD) and four multiple ascending dose (MAD) cohorts, eight subjects/cohort. Subjects were randomized in a 6:2 ratio to receive 3-hour IV infusions of APX001 or placebo. SAD Cohorts 1–6 received single doses of 10, 30, 100, 200, 275, and 350 mg, respectively. MAD Cohorts 7–10 received doses of 50, 150, 300, and 600 mg, respectively, once daily for 14 days. Pharmacokinetic (PK) parameters for APX001A in plasma were calculated using non-compartmental analysis. Safety monitoring and intense PK sampling occurred throughout the trial. A safety committee reviewed the PK and safety data to determine dose escalation steps. Plasma exposure to APX001A was linear, dose proportional, with low intersubject variability and a half-life of ~2.5 days. As expected from the half-life and dosing frequency, accumulation of APX001A was observed in the MAD cohorts. A single APX001 dose of 350 mg maintained drug levels above the minimum inhibitory concentration (MIC) of Candida and Aspergillus for one week. The 600 mg/day AUC0–24on Day 14 was 245 μg.hours/mL. APX001 was well tolerated across all doses with no clinically significant adverse events observed. One subject discontinued due to the adverse event (AE) of flu. There were no dose limiting toxicities. Most of the AEs were mild, transient and required no treatment. The most common AE was headache. Target exposures of APX001A for efficacy against Candida and Aspergillus as well as the high MIC rare mold pathogens were exceeded at doses that are safe and well tolerated. M. R. Hodges, Amplyx Pharmaceuticals: Employee, Salary; E. Ople, Amplyx Pharmaceuticals Inc.: Employee, Salary. K. J. Shaw, Amplyx Pharmaceuticals Inc.: Employee, Salary; R. Mansbach, Amplyx Pharmaceuticals Inc.: Consultant, Consulting fee; S. J. Van Marle, PRA Health Sciences: Employee, Salary. E. J. Van Hoogdalem, PRA Health Sciences: Employee, Salary. P. Wedel, Amplyx Pharmaceuticals Inc.: Employee, Salary. W. Kramer, Amplyx Pharmaceuticals Inc.: Consultant, Consulting fee.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
“Transient headache was the most frequently described AE [102].”
BackgroundShaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229
Self-citationIn Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
Hager, C. L., Larkin, E. L., Long, L., Zohra Abidi, F., Shaw, K. J., & Ghannoum, M. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02319-17 · Cited by 139
Self-citationIn Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00523-18 · Cited by 121
Self-citationAlkhazraji, S., Gebremariam, T., Alqarihi, A., Gu, Y., Mamouei, Z., Singh, S., Wiederhold, N. P., Shaw, K. J., & Ibrahim, A. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01735-19 · Cited by 97
“fosmanogepix phase 1 clinical studies have shown favorable PK, allowing once-daily dosing with high bioavailability ( 90%) and no food effect (9, 21).”
BackgroundResultSelf-citation
Metadata
- Authors
- Hodges, M. R., Ople, E., Shaw, K. J., Mansbach, R., Van Marle, S. J., Van Hoogdalem, E.-J., Wedel, P., & Kramer, W.
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2017
- Volume
- 4
- Issue
- suppl_1
- Pages
- S526-S526
- ISSN
- 2328-8957 (ISSN-L)
- OpenAlex
- W2754274550
- Cited by
- 40
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects. https://app.cochat.ai/papers/10.1093/ofid/ofx163.1370
- The paper
- Hodges, M. R., Ople, E., Shaw, K. J., Mansbach, R., Van Marle, S. J., Van Hoogdalem, E.-J., Wedel, P., & Kramer, W. (2017). First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofx163.1370
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.